Safety of Administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in Youths and Young Adults with a History of Acute Lymphoblastic Leukaemia and Allergy to PEG-Asparaginase

Catherine Mark; Sumit Gupta; Angela Punnett; Julia Upton; Julia Orkin; Adelle Atkinson; Lindsay Clarke; Alice Heisey; Christine McGovern; Sarah Alexander

doi:10.22541/au.162497659.90604960/v1

loading page

Safety of Administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in Youths and Young Adults with a History of Acute Lymphoblastic Leukaemia and Allergy to PEG-Asparaginase

Catherine Mark,
Sumit Gupta,
Angela Punnett,
Julia Upton,
Julia Orkin,
Adelle Atkinson,
Lindsay Clarke,
Alice Heisey,
Christine McGovern,
Sarah Alexander

Abstract

Vaccination is a critical tool in the prevention of COVID-19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently in North America only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved individuals 12 to 17 years of age. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive Peg-asparaginase and 10-30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG-asparaginase allergy.

27 Jun 2021Submitted to Pediatric Blood & Cancer

Show details

Hide details

27 Jun 2021Submission Checks Completed

27 Jun 2021Assigned to Editor

29 Jun 2021Reviewer(s) Assigned

13 Jul 2021Review(s) Completed, Editorial Evaluation Pending

13 Jul 2021Editorial Decision: Revise Minor

15 Jul 20211st Revision Received

15 Jul 2021Submission Checks Completed

15 Jul 2021Assigned to Editor

19 Jul 2021Reviewer(s) Assigned

28 Jul 2021Review(s) Completed, Editorial Evaluation Pending

02 Aug 2021Editorial Decision: Accept

Abstract

Peer review status:ACCEPTED